Ironwood Pharmaceuticals reports Q1 activity — 3 key updates

Ironwood Pharmaceuticals provided an update on its first quarter 2015 activities, including their gastrointestinal product candidates.

Here are three highlights from the first quarter:

1. Data from Ironwood's investigational gastric retentive bile acid sequestrant demonstrated improvements in relief of heartburn and other symptoms.

2. Ironwood reported continued activity with a Phase IIa clinical study evaluating the ability of guanylate cyclase-C agonist to provide diabetic gastroparesis symptom relief.

3. Dosing began in a Phase I clinical study of he first clinical compound in a broad library of sGC stimulators for the potential treatment of cardiovascular disease.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast